Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyIndolent LymphomasDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbSubgroupB-ALLICD10C82.-C82.7C82.9C83.3C91.0-C91.1-MeSHLymphoma, Large B-Cell, DiffusePrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceChemotherapyChemo-substanceBendamustineCyclophosphamideCytarabineEtoposideFludarabineChemo-substanceBendamustineCyclophosphamideCytarabineEtoposideFludarabineChemo-substanceBendamustineCyclophosphamideCytarabineEtoposideFludarabineChemo-substanceBendamustineCyclophosphamideCytarabineEtoposideFludarabineNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances23Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionRisksAnemia Hb below 8g/dlEmetogenicity (MASCC/ESMO)HypertensionLymphopeniaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorLiu E Maude SLSchuster SJDiseaseB-ALL, CD19+ rezidivierte oder refraktäre B-ALL, Lymphodepletion vor CAR T-Zell TherapieB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR-T-Zell TherapieDLBCL, Rezidiv nach mind. 2 Vortherapien, ASCT ungeeignet oder bereits unterzogen, Lymphodepletion vor CAR T-Zell TherapieOriginAbramson Cancer Center, University of Pennsylvania, Philadelphia, JULIET trialPerelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, ELIANA trialUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 5 protocols foundProtocols under revision.Bendamustine 90, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1830 V1.0)Cytarabine 500 / Etoposide 150, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1832 V1.0)Fludarabine 25 / Cyclophosphamide 250, diffuse large B-non-Hodgkin Lymphoma, Lymphodepletion (PID1829 V1.0)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)Fludarabine 30 / Cyclophosphamide 500, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1831 V1.0)
